Benzinga | Aug 13, 2020 08:36AM EDT

NanoVibronix Announces First Shipments Of New UroShield Devices

ELMSFORD, N.Y., Aug. 13, 2020 /PRNewswire/ --NanoVibronix, Inc., (NASDAQ:NAOV), a medical device company that produces the UroShield(r), PainShield(r) and WoundShield(r), and WoundShield(r) Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that it has shipped its first orders of the new UroShield(r) device to the United Kingdom.

Contemporaneous with the fulfilment of new orders, the Company has been engaged with the National Institute of Clinical Evidence (NICE) on readying the new version of UroShield(r) for submission for NICE Official Guidance. This important step is intended to help accelerate market access to all NHS patients at risk of catheter associated urinary tract infections (CAUTI). The Company is also pursuing a similar registration process in Australia via the Therapeutic Goods Administration (TGA), as well as other regulatory agencies.

"The global Covid-19 pandemic has reinforced the widely known importance of preventing co-morbidity, which we believe may complicate and compromise patients stricken with the Covid-19 virus," said Brian Murphy, CEO of NanoVibronix. "UroShield has proven its effectiveness through several randomized controlled trials to significantly reduce Catheter Associated Urinary Tract Infection (CAUTI), one of the leading factors associated with Hospital Acquired Infection and increased hospital stays. We remain very excited about the potential for this product to improve the lives of patients."

UroShield(r) is an ultrasound-based product that is designed to prevent bacterial colonization and biofilm on indwelling urinary catheters and increase antibiotic efficacy, ultimately reducing the incidence of catheter-associated urinary tract infections (CAUTI). UroShield(r) is also intended to decrease pain and discomfort associated with urinary catheter use.